Home›Stock Screener›AstraZeneca Pharma›Intrinsic Value

AstraZeneca Pharma Intrinsic Value

AstraZeneca Pharma intrinsic value. AstraZeneca Pharma (ASTRAZEN) median intrinsic value is ₹2445.20 from 10 valuation models (range ₹1834–₹10556), vs current price ₹6113.00 — -60.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Analyse AstraZeneca Pharma ownership pattern to track promoter, FII and institutional holdings.

Market Price (CMP)
₹6113.00
Primary Intrinsic Value
₹1833.90
Market Cap
₹3056 Cr
-60.0% Downside
Median Value
₹2445.20
Value Range
₹1834 - ₹10556
Assessment
Trading Above Calculated Value
Safety Margin
-100.0%

ASTRAZEN Valuation Methods Summary — DCF, Graham Number & P/E

AstraZeneca Pharma intrinsic value across 10 models vs current price ₹6113.00 — upside/downside and value range per method. For current market price and key ratios, visit AstraZeneca Pharma share price screener.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹1833.90 ₹1467.12 - ₹2200.68 -70.0% EPS: ₹71.10, Sector P/E: 22x
Book Value Method asset ₹3492.00 ₹3142.80 - ₹3841.20 -42.9% Book Value/Share: ₹1746.00, P/B: 2.0x
Revenue Multiple Method revenue ₹10556.00 ₹9500.40 - ₹11611.60 +72.7% Revenue/Share: ₹5278.00, P/S: 2.0x
EBITDA Multiple Method earnings ₹5420.00 ₹4878.00 - ₹5962.00 -11.3% EBITDA: ₹271.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹2445.20 ₹1956.16 - ₹2934.24 -60.0% CF Growth: 5.0%, Discount: 15%
PEG Ratio Method growth ₹1833.90 ₹1650.51 - ₹2017.29 -70.0% EPS Growth: 15.7%, Fair P/E: 12.5x
Growth Adjusted P/E growth ₹1833.90 ₹1650.51 - ₹2017.29 -70.0% Revenue Growth: 15.0%, Adj P/E: 16.1x
ROE Based Valuation profitability ₹5696.00 ₹5126.40 - ₹6265.60 -6.8% ROE: 20.4%, P/E Multiple: 16x
Graham Defensive Method conservative ₹1833.90 ₹1650.51 - ₹2017.29 -70.0% EPS: ₹71.10, BVPS: ₹1746.00
Dividend Yield Method dividend ₹1833.90 ₹1650.51 - ₹2017.29 -70.0% DPS: ₹36.00, Target Yield: 2.5%
Method Types: Earnings Asset DCF Growth Dividend Conservative

ASTRAZEN Intrinsic Value vs Market Price — All Valuation Models

AstraZeneca Pharma fair value range ₹1834–₹10556 vs current market price ₹6113.00 across 10 valuation models. Browse ASTRAZEN annual financials for revenue, profit, balance sheet and cash flow data.

ASTRAZEN Intrinsic Value Analysis — Undervalued or Overvalued?

AstraZeneca Pharma median intrinsic value ₹2445.20, current price ₹6113.00 — Trading Above Calculated Value by 60.0%, margin of safety -100.0%.

What is the intrinsic value of ASTRAZEN?

Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of AstraZeneca Pharma (ASTRAZEN) is ₹2445.20 (median value). With the current market price of ₹6113.00, this represents a -60.0% variance from our estimated fair value.

The valuation range spans from ₹1833.90 to ₹10556.00, indicating ₹1833.90 - ₹10556.00.

Is ASTRAZEN undervalued or overvalued?

Based on our multi-method analysis, AstraZeneca Pharma (ASTRAZEN) appears to be trading above calculated value by approximately 60.0%.

ASTRAZEN Financial Health — Key Ratios vs Industry Benchmarks

AstraZeneca Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 20.4% Industry Standard: 15%+ Above 15% Measures shareholder return efficiency
Operating Margin 9.0% Industry Standard: 20%+ Below 10% Indicates operational efficiency level
Asset Turnover Ratio 1.33x Industry Standard: 1.0x+ Above 1.0x Measures asset utilization efficiency

ASTRAZEN Cash Flow Quality — Operating & Free Cash Flow

AstraZeneca Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹-15 Cr ₹-15 Cr Negative Cash Flow 3/10
March 2025 ₹65 Cr ₹65 Cr Positive Free Cash Flow 8/10
March 2024 ₹28 Cr ₹28 Cr Positive Free Cash Flow 8/10
March 2023 ₹58 Cr ₹58 Cr Positive Free Cash Flow 8/10
March 2022 ₹101 Cr ₹101 Cr Positive Free Cash Flow 8/10